BioNTech to Report Third Quarter 2024 Financial Results and Corporate Update on November 4, 2024
BioNTech SE (Nasdaq: BNTX) has announced that it will release its financial results for the third quarter of 2024 on Monday, November 4, 2024. The company will also host a conference call and webcast on the same day at 8:00 a.m. ET (2:00 p.m. CET) to discuss the financial results and provide a corporate update.
Investors, financial analysts, and the general public can access the live conference call by registering through a provided link. The slide presentation and audio of the webcast will be available via another link. Participants can also access the materials through the 'Events & Presentations' page in the Investor Relations section of BioNTech's website. A replay of the webcast will be archived on the company's website for 30 days following the call.
BioNTech SE (Nasdaq: BNTX) ha annunciato che rilascerà i suoi risultati finanziari per il terzo trimestre del 2024 il lunedì 4 novembre 2024. L'azienda ospiterà anche una conferenza telefonica e webcast lo stesso giorno alle 8:00 ET (2:00 p.m. CET) per discutere i risultati finanziari e fornire un aggiornamento aziendale.
Investitori, analisti finanziari e il pubblico generale possono accedere alla conferenza telefonica in diretta registrandosi attraverso un link fornito. La presentazione in diapositive e l'audio del webcast saranno disponibili tramite un altro link. I partecipanti possono anche accedere ai materiali attraverso la pagina 'Eventi e Presentazioni' nella sezione Relazioni con gli Investitori del sito web di BioNTech. Una registrazione del webcast sarà archiviata sul sito dell'azienda per 30 giorni dopo la chiamata.
BioNTech SE (Nasdaq: BNTX) ha anunciado que publicará sus resultados financieros del tercer trimestre de 2024 el lunes 4 de noviembre de 2024. La empresa también llevará a cabo una llamada de conferencia y webcast el mismo día a las 8:00 a.m. ET (2:00 p.m. CET) para discutir los resultados financieros y proporcionar una actualización corporativa.
Los inversores, analistas financieros y el público en general pueden acceder a la llamada de conferencia en vivo registrándose a través de un enlace proporcionado. La presentación de diapositivas y el audio del webcast estarán disponibles a través de otro enlace. Los participantes también pueden acceder a los materiales a través de la página 'Eventos y Presentaciones' en la sección de Relaciones con Inversores del sitio web de BioNTech. Una grabación del webcast se archivará en el sitio web de la empresa durante 30 días después de la llamada.
BioNTech SE (Nasdaq: BNTX)는 2024년 3분기 재무 결과를 2024년 11월 4일 월요일에 발표할 것이라고 발표했습니다. 회사는 같은 날 전화 회의 및 웹캐스트를 동부 표준시 기준 8:00 a.m. (중부 유럽 표준시 기준 2:00 p.m.)에 개최하여 재무 결과를 논의하고 기업 업데이트를 제공할 예정입니다.
투자자, 재무 분석가 및 일반 대중은 제공된 링크를 통해 실시간 전화 회의에 등록하여 접근할 수 있습니다. 슬라이드 프레젠테이션과 웹캐스트의 오디오는 다른 링크를 통해 제공됩니다. 참가자는 BioNTech 웹사이트의 투자자 관계 섹션의 '이벤트 및 발표' 페이지를 통해 자료에 접근할 수도 있습니다. 웹캐스트의 재생 영상은 통화 후 30일 동안 회사 웹사이트에 보관됩니다.
BioNTech SE (Nasdaq: BNTX) a annoncé qu'elle publiera ses résultats financiers pour le troisième trimestre 2024 le lundi 4 novembre 2024. L'entreprise organisera également un appel conférence et un webcast le même jour à 8h00 ET (14h00 CET) pour discuter des résultats financiers et fournir une mise à jour de l'entreprise.
Les investisseurs, les analystes financiers et le grand public peuvent accéder à l'appel conférence en direct en s'inscrivant via un lien fourni. La présentation des diapositives et l'audio du webcast seront disponibles via un autre lien. Les participants peuvent également accéder aux documents via la page 'Événements & Présentations' dans la section Relations avec les Investisseurs du site web de BioNTech. Un enregistrement du webcast sera archivé sur le site de l'entreprise pendant 30 jours suivant l'appel.
BioNTech SE (Nasdaq: BNTX) hat bekannt gegeben, dass es seine finanziellen Ergebnisse für das dritte Quartal 2024 am Montag, den 4. November 2024, veröffentlichen wird. Das Unternehmen wird am selben Tag um 8:00 Uhr ET (14:00 Uhr MEZ) eine Telefonkonferenz und Webcast veranstalten, um die finanziellen Ergebnisse zu erörtern und ein Unternehmensupdate zu geben.
Investoren, Finanzanalysten und die breite Öffentlichkeit können auf die Live-Telefonkonferenz zugreifen, indem sie sich über einen bereitgestellten Link registrieren. Die Präsentation und die Audioübertragung des Webcasts sind über einen weiteren Link verfügbar. Teilnehmer können die Materialien auch über die Seite 'Veranstaltungen & Präsentationen' im Bereich Investor Relations der BioNTech-Website abrufen. Eine Aufzeichnung des Webcasts wird 30 Tage nach dem Anruf auf der Unternehmenswebsite archiviert.
- None.
- None.
MAINZ, Germany, October 21, 2024 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the third quarter 2024 on Monday, November 4, 2024. Additionally, the Company will host a conference call and webcast that day at 8:00 a.m. ET (2:00 p.m. CET) for investors, financial analysts and the general public to discuss its financial results and provide a corporate update.
To access the live conference call via telephone, please register via this link. Once registered, dial-in numbers and a PIN will be provided. It is recommended to register at least one day in advance. The slide presentation and audio of the webcast will be available via this link.
Participants may also access the slides and the webcast of the conference call via the “Events & Presentations” page in the Investor Relations section of the Company’s website at www.BioNTech.com. A replay of the webcast will be made available shortly after the call and archived on the Company’s website for 30 days following the call.
About BioNTech
Biopharmaceutical New Technologies (BioNTech) is a global next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. BioNTech exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor (CAR) T cells, several protein-based therapeutics, including bispecific immune checkpoint modulators, targeted cancer antibodies and antibody-drug conjugate (ADC) therapeutics, as well as small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global and specialized pharmaceutical collaborators, including Biotheus, DualityBio, Fosun Pharma, Genentech, a member of the Roche Group, Genevant, Genmab, MediLink, OncoC4, Pfizer and Regeneron.
For more information, please visit www.BioNTech.com.
CONTACTS
Investor Relations
Michael Horowicz
Investors@biontech.de
Media Relations
Jasmina Alatovic
+49 (0)6131 9084 1513
Media@biontech.de
FAQ
When will BioNTech (BNTX) report its Q3 2024 financial results?
What time is BioNTech's (BNTX) Q3 2024 earnings call scheduled for?
How can investors access BioNTech's (BNTX) Q3 2024 earnings call?
Where can I find the slides for BioNTech's (BNTX) Q3 2024 earnings presentation?
